Compare Abbott Laboratories (ABT) vs Appian Corp (APPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Appian Corp — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Appian Corp trades at $24.27 (market cap $1.81B). The key difference: Abbott Laboratories is far larger — about 92.2× Appian Corp's market cap, and Abbott Laboratories pays a 2.63% dividend while Appian Corp pays none. Which is the better fit depends on your goals.
| ABT | APPN | |
|---|---|---|
Market Cap | $166.94B | $1.81B |
Sector | Health | Technology |
52-Week High | $136.62 | $45.64 |
52-Week Low | $82.57 | $18.72 |
Enterprise Value | $193.69B | $1.90B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Appian (APPN) trades at $24.68, up 1.15% with bullish technical signals from moving averages. The company shows strong revenue growth reaching $727M in 2025 and has beaten earnings estimates for three consecutive quarters. However, profitability remains minimal with a net margin of just 0.12% and negative shareholder equity of -$32.64M. Recent CEO stock sales and mixed analyst sentiment create uncertainty despite positive AI-driven business developments.
Appian presents a growth story with improving cash flow and AI positioning, but faces significant profitability challenges and negative equity. The stock trades near analyst consensus target of $26.20, suggesting limited upside. Key risks include sustained unprofitability and high debt levels, while opportunities lie in enterprise AI adoption and cloud revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →
